- Home
- NXTC vs ARBB Comparison
NXTC vs ARBB Comparison
Compare NXTC & ARBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- ARBB
- Stock Information
- Founded
- NXTC 2015
- ARBB 1997
- Country
- NXTC United States
- ARBB Singapore
- Employees
- NXTC N/A
- ARBB N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- ARBB EDP Services
- Sector
- NXTC Health Care
- ARBB Technology
- Exchange
- NXTC Nasdaq
- ARBB Nasdaq
- Market Cap
- NXTC 13.9M
- ARBB 11.9M
- IPO Year
- NXTC 2019
- ARBB 2023
- Fundamental
- Price
- NXTC $0.45
- ARBB $6.38
- Analyst Decision
- NXTC Strong Buy
- ARBB Strong Buy
- Analyst Count
- NXTC 2
- ARBB 1
- Target Price
- NXTC $3.50
- ARBB $20.00
- AVG Volume (30 Days)
- NXTC 346.6K
- ARBB 13.5K
- Earning Date
- NXTC 07-31-2025
- ARBB 07-11-2025
- Dividend Yield
- NXTC N/A
- ARBB N/A
- EPS Growth
- NXTC N/A
- ARBB N/A
- EPS
- NXTC N/A
- ARBB N/A
- Revenue
- NXTC N/A
- ARBB $24,425,491.00
- Revenue This Year
- NXTC N/A
- ARBB N/A
- Revenue Next Year
- NXTC N/A
- ARBB N/A
- P/E Ratio
- NXTC N/A
- ARBB N/A
- Revenue Growth
- NXTC N/A
- ARBB N/A
- 52 Week Low
- NXTC $0.22
- ARBB $3.22
- 52 Week High
- NXTC $1.82
- ARBB $18.60
- Technical
- Relative Strength Index (RSI)
- NXTC 44.08
- ARBB 43.40
- Support Level
- NXTC $0.45
- ARBB $6.49
- Resistance Level
- NXTC $0.49
- ARBB $7.46
- Average True Range (ATR)
- NXTC 0.06
- ARBB 0.54
- MACD
- NXTC -0.01
- ARBB 0.14
- Stochastic Oscillator
- NXTC 0.74
- ARBB 62.13
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About ARBB ARB IOT Group Limited
ARB IOT Group Ltd is engaged in provision of hardware and software of Internet of Things Solutions to meet customers' demand in four business lines, which are IoT Smart Home and Buildings, IoT Smart Agriculture, IoT System Development, and IoT Gadget Distribution. The company delivers holistic solutions with full turnkey deployment from designing, installation, testing, pre-commissioning, and commissioning of various IoT systems and devices as well as integration of automated systems, including installation of wire and wireless and mechatronic works. The company has two operating segments: Internet of Things ('IoT'), Investment holding and others. It earns its maximum profit from the Internet of Things (IoT) segment.